Application Effect of Secukinumab in Patients with Moderate to Severe Plaque Psoriasis
Objective:To investigate the application effect of Secukinumab in patients with moderate to severe plaque psoriasis.Method:A total of 72 patients with moderate to severe plaque psoriasis who treated in Changshu First People's Hospital from January 2022 to December 2023 were selected as the research objects,the patients were divided into the observation group and the control group according to the random number table method,with 36 cases in each group.The control group was treated with Compound Calcipotriol Ointment for external use,and the observation group was treated with Secukinumab on the basis of the control group.The therapeutic effect,serum laboratory indexes and adverse reactions were compared between two groups.Result:After 1 month and 3 months of treatment,the psoriasis area and severity index(PASI)scores and dermatology life quality index(DLQI)scores of two groups were lower than those before treatment,and those in the observation group were lower than those in the control group,the differences were statistically significant(P＜0.05);after 3 months of treatment,the levels of serum tumor necrosis factor-α(TNF-α),interleukin-23(IL-23),interleukin-17(IL-17)and helper T cell 17(Th17)in the two groups were lower than those before treatment,and those in the observation group were lower than the control group,the differences were statistically significant(P＜0.05);there was no significant difference in the incidence of adverse reactions between two groups(P＞0.05).Conclusion:The application of Secukinumab in patients with moderate to severe plaque psoriasis can reduce inflammatory response,improve clinical symptoms,improve quality of life,and do not increase adverse reactions,with high safety.
Plaque psoriasisSecukinumabCompound Calcipotriol OintmentInflammatory responseClinical symptomsQuality of life
国家科技期刊平台
NSTL
万方数据
